The company has agreed to a takeover bid that values it at roughly €171 million ($186.3 million).
The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.
The company is integrating its newly purchased LIMS and genome interpretation and reporting capabilities to provide a single platform for cancer and inherited disease diagnostics.
The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.
NantOmics hopes to enhance its diagnostics platform with the addition of Genos' sequencing technology and expertise.
The purchase from Janssen of a liquid biopsy test for circulating tumor cells marks Menarini-Silicon's entry into the US diagnostics market.
Privately held TransCell specializes in primary cell-based phenotypic screening assays.
The business was acquired by two private investment groups and a management group led by Prometheus Laboratories' former CEO.
The deal is expected to strengthen MedDay's existing cerebrospinal fluid-based metabolomics research platform.
Hygiena will sell DuPont Diagnostics products through its Qualicon Diagnostics unit.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.